Orchestra BioMed Holdings, Inc. (OBIO)

Market Cap	36.81M
Revenue (ttm)	1.65M
Net Income (ttm)	-48.59M
Shares Out	2.41M
EPS (ttm)	-21.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	44,220
Open	15.72
Previous Close	15.69
Day's Range	14.06 - 15.72
52-Week Range	7.49 - 19.18
Beta	n/a
Analysts	Buy
Price Target	19.04 (+24.77%)
Earnings Date	Jan 25, 2023

About OBIO

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of h...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 45
• Stock Exchange: NASDAQ
• Ticker Symbol: OBIO

Analyst Forecast

According to 8 analysts, the average rating for OBIO stock is "Buy." The 12-month stock price forecast is $19.04, which is an increase of 24.77% from the latest price.

Price Target

$19.04

(24.77% upside)

Analyst Consensus: Buy